Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B immunoglobulin prophylaxis

Liver Transplantation

Volumn 12, Issue 2, 2006, Pages 253-258

  Zheng, Shusen ^a   Chen, Yaomin ^a   Liang, Tingbo ^a   Lu, Anwei ^a   Wang, Weilin ^a   Shen, Yan ^a   Zhang, Min ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; CYCLOSPORIN; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; METHIONINE; MYCOPHENOLIC ACID; PREDNISONE; THYROXINE; TSUKUBAENOLIDE;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LIVER FAILURE; LIVER TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUTANT; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT INFECTION; RELAPSE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME;

ADULT; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS B, CHRONIC; HUMANS; IMMUNOGLOBULINS; LAMIVUDINE; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROBABILITY; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 33244474879     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.20701     Document Type: Article

References (27)

1. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung J, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus related liver disease. Hepatology 1991;13:619-626.
2. O'Grady JG, Smith HM, Davies SE, Daniels HM, Donaldson PT, Tan KC, et al. Hepatitis B virus re-infection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992;14:104-111.
3. Marzano A, Gaia S, Ghisetti V, Carenzi S, Premoli A, Debernardi-Venon W, et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 2005;11:402-409.
4. Anselmo DM, Ghobrial RM, Jung LC, Weaver M, Cao C, Saab S, et al. New era of liver transplantation for hepatitis B: a 17-year single-center experience. Ann Surg 2002;235: 611-620.
5. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993;329:1842-1847.
6. Perrilo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001;424-432.
7. Roche B, Feray C, Gigou M, Roque-Afonso AM, Arulnaden JL, Delvart V, et al. HBV DNA persistence 10 years after transplantation despite successful anti-HBs passive immunoprophylaxis. Hepatology 2003;38:86-95.
8. Markowitz JS, Martin P, Conral AJ, Markmann JF, Seu P, Yersiz H, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28:585-589.
9. Han SH, Ofman J, Holt C, King K, Kunder G, Chen P, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000;6:741-748.
10. Marzano A, Salizzoni M, Debernardi-Venon W, Smedile A, Franchello A, Ciancio A, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001;34:903-910.
11. Roche B, Samuel D, Roque AM, Feray C, Petit AM, Vasseur B, et al. Intravenous anti-HBs Ig combined with oral lamivudine for prophylaxis against HBV recurrence after liver transplantation (Abstract). J Hepatol 1999;30:A80.
12. Zhu JP, Zhang TL, Li L, Yuan J, Song SB, Xiu DR, et al. Prevention and treatment of hepatitis B recurrence after liver transplantation. Hepatolobiliary Pancreat Dis Int 2003;2:500-503.
13. Gow PJ, Mutimer D. Mechanism of hepatitis B virus escape after immunoglobulin therapy. Curr Opin Infect Dis 2000;13:643-646.
14. Shouval D, Samuel D. Hepatitis B immune globulin to prevent HBV graft reinfection following liver transplantation: a concise review. Hepatology 2000:32:1189-1195.
15. Liaw YF. Results of lamivudine trials in Asia. J Hepatol 2003;39(Suppl):S111-S115.
16. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1741-1722.
17. Saab S, Kim M, Wright TL, Han SH, Martin P, Busuttil RWL. Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus. Gastroenterology 2000;119:1382-1384.
18. Starkel P, Horsmans Y, Geubel A, Ciccarelli O, Goubau P, Rahier J, Lerut J. Favorable outcome of orthotopic liver transplantation in a patient subacute liver failure because of the emergence of a hepatitis B YMDD escape mutant virus. J Hepatol 2001;36:679-681.
19. Angus PW, McCaughan GW, Gane EJ, Crawford DHG, Harley H, the Australasian Liver Transplant Study Group. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000;6:429-433.
20. Dodson SF, de Vera ME, Bonham CA, Geller DA, Rakela J, Fung JJ. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transplant 2000;6:434-439.
21. Lo CM, Cheug ST, Lai CL, Liu CL, OL Ng, Yuen MF, et al. Liver transplantation in patients with chronic hepatitis B using lamivudine prophylaxis. Ann Surg 2001;233:276-281.
22. Neff GW, O'Brien CB, Nery J, Shire N, Montalbano M, Ruiz P, et al. Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. Liver Transpl 2005;11:1372-1378.
23. Samuel D, Bismuth A, Mathieu D, Arulnaden JL, Reynes M, Benhamou JP, et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991;337:813-815.
24. Nymann T, Shokouh-Amiri MH, Vera SR, Riely CA, Alloway RR, Gaber AO. Prevention of hepatitis B recurrence with indefinite hepatitis B immune globulin (HBIG) prophylaxis after liver transplantation Clin Transpl 1996;10: 663-667.
25. McGory RW, Ishitani MB, Oliveira WM, Stevenson WC, McCulough CS, Dciskson RC, et al. Improved clinical outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996;61:1358-1364.
26. Di Polo D, Tisone G, Piccolo P, Lenci I, Zazza S, Angelico M, et al. Low-dose hepatitis B immunoglobulin given "on demand" in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B infection in the long-term follow-up after liver transplantation. Transplantation 2004;77:1203-1208.
27. Marzano A, Lampertico P, Mazzaferro V, Carenzi S, Vigano M, Romito R, et al. Prophylaxls of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transpl 2005;11:532-538.